TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age from 60 days to 90 days;~* Adults, parent(s) or guardians are able to understand and sign informed consent for participation;~* Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;~* Infants no vaccinated with poliovaccine or other preventive biologicals in recent 7 days;~* Axillary temperature ≤37℃.~Exclusion Criteria:~* Have medical record of participants or their family on allergy, convulsion, falling sickness, encephalopathy and psychopathy;~* Low platelet or bleeding disorder do not allow vaccination into the muscle;~* Have damaged or lower immunological function;~* Received blood, plasma or immunoglobulin treatment since birth;~* Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );~* Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.~Exclusion Criteria for doses 2 and 3~* Have serious anaphylaxis or high fever, convulsion during first dose;~* Have any circus of Exclusion Criteria after Eligible for study;~* Have serious adverse event which related to previous vaccination; Withdrawal and Discontinuance Criteria;~* Received necessary or interference study drugs such as: immune-inhibition or immune-stimulating agents;~* Vaccinated with any other vaccine（except DTP）;~* Stop observation determined by investigator owing to occurring serious adverse event.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
- Cohort 2: (Type: EXPERIMENTAL): Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Head Lice Study Product Comparison

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject Inclusion Criteria~* Current lice infestation, confirmed by school nurse. Must have live lice - not just eggs. A minimum of one live louse and 10 viable eggs must be seen or three live lice.~* Male or female child; age 3 - 12~* Willing to participate in study, and parent/guardian sign informed consent~* Parent/guardian must be able to read and follow directions and complete all questionnaires~* For children/parents who agree to the experimental arm of the study, agree not to use any other head lice product or home remedy lice treatment during the study.~Exclusion Criteria:~* No live lice, only eggs.~* Less than three live lice observed with less than ten viable eggs~* No hair on the head~* Buzz cut or crew cut~* Use of other lice treatment or home remedy lice treatment within the past 4 weeks~* Chronic scalp disorder (such as psoriasis) that would limit the school nurse's ability to detect lice and/or identify adverse events~* Currently taking an antibiotic~* Does not follow instructions.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- LICEMD (Type: EXPERIMENTAL): Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
- Standard Head lice product (Type: ACTIVE_COMPARATOR): Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic) NSCLC with adenocarcinoma histology.~* Never smokers or light ex-smokers.(ceased smoking at least 15 years before Day 1 of study treatment and 10 pack-years or fewer)~Exclusion Criteria:~* Had prior chemotherapy, biological (including targeted therapies such as EGFR and vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.~* Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): gefitinib
- 2 (Type: ACTIVE_COMPARATOR): Carboplatin/Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16 years or more~* Confirmed diagnosis of MYH9-related disease~* Average platelet count for the previous year less than 50x10e9/L~* Written informed consent~Exclusion Criteria:~* Diseases known to involve the risk of thromboembolic events (e.g. atrial fibrillation)~* History of thrombosis within 1 year~* Use of drugs that affect platelet function (including but not limited to, aspirin, clopidogrel or NSAIDS) or anti-coagulants~* Females who are pregnant or nursing (a negative pregnancy test in required before enrollment of fertile women)~* Formal refusal of any recommendation of a safe contraception~* Alcohol or drug addiction~* Altered renal function as defined by creatinine of 20 mg/L or more~* Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioral problems. HCV positivity and liver diseases will not be considered an exclusion criterion since a phase II study showed that eltrombopag was effective and safe in this patient population.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eltrombopag (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (1) Male gender (2) self-reported anal sex with men in the prior three months while under the influence of alcohol (3) at least one binge drinking (five or more drinks on a single occasion) session per week in the prior three months; (4) interested in reducing binge alcohol consumption; (5) HIV-negative by rapid antibody test or medical record documentation of HIV infection (HIV positive participants); (6) no current acute illnesses requiring prolonged medical care; (7) no chronic illnesses that are likely to progress clinically during trial participation; (8) able and willing to provide informed consent and adhere to visit schedule; (9) age 18-70 years; (10) baseline CBC, total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, and electrolytes without clinically significant abnormalities as determined by study clinician in conjunction with symptoms, physical exam, and medical history.~Exclusion Criteria:~* (1) Any psychiatric (e.g. depression with suicidal ideation) or medical condition that would preclude safe participation in the study; (2) known allergy/previous adverse reaction to naltrexone; (3) current use of/ dependence on any opioids or a known medical condition which currently requires/may likely require opioid analgesics; (4) opioid-positive urine at enrollment; (5) current CD4 count \< 200 cells/mm3 (6) moderate/severe liver disease (AST, ALT \> 3 times upper limit of normal); (7) impaired renal function (creatinine clearance \< 50 ml/min); (8) currently participating in another intervention research study with potential overlap; (9) alcohol dependence as determined by SCID criteria (participants with non-dependent alcohol use disorders/symptoms of alcohol abuse \[per DSM-IV\] are eligible) (10) any condition that, in the principal investigator and/or study clinician's judgment interferes with safe study participation or adherence to study procedures; (11) not having a cell-phone that can send and receive text messages.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 50mg, as needed
- Naltrexone (Type: ACTIVE_COMPARATOR): Naltrexone 50mg, as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in United Therapeutics Study TDE-PH-310~* All women of childbearing potential (WOCBP) must have practiced true abstinence from intercourse when it was in line with their preferred and usual lifestyle or used 2 different forms of highly effective contraception for the duration of the study and for at least 30 days after discontinuing study medication.~* Males who participated in the study must have used a condom during the length of the study and for at least 48 hours after their last dose of study medication.~Exclusion Criteria:~* The subject was pregnant or lactating.~* The subject had received infused or inhaled prostacyclin therapy for 29 days or more.~* The subject was prematurely discontinued from TDE-PH-310 for reasons other than a clinical worsening event.~* The subject developed a concurrent illness or condition during the conduct of TDE-PH-310 which, in the opinion of the Investigator, would represent a risk to their overall health if they enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- UT-15C (Type: EXPERIMENTAL): Open label access

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Note: accrual into Arms A-2 and B-2 of this study has been discontinued.~Inclusion Criteria for Step 1~* HIV infected~* Experiencing a loss of fat since starting anti-HIV therapy, especially in the arms and legs~* Receiving anti-HIV therapy of 3 or more drugs, including either stavudine or zidovudine, for 24 weeks or more prior to study screening~* Viral load less than 500 copies/ml at study screening and within 60 days prior to study entry~* CD4 count of 100 or more cells/mm3 obtained within 60 days prior to study entry~* Approved methods of contraception~* Written informed consent~Exclusion Criteria for Step 1~* Currently receiving abacavir sulfate or have received abacavir sulfate in the past AND any or all of the following: unable to tolerate lopinavir/ritonavir (LPV/r) or nevirapine (NVP); failed anti-HIV treatment containing LPV/r, any other 2 PIs, or any other NNRTI; taking lamivudine (3TC) or tenofovir disoproxil fumarate (TDF) for hepatitis B virus infection and need to remain on a 3TC- or TDF-containing regimen; or have a low chance of response to LPV/r plus NVP~* Cancer treatment 6 months prior to study entry~* Initiated oral drugs to lower blood sugar level 24 weeks prior to study entry. Patients who have taken oral drugs to lower their blood sugar levels for 24 weeks or more prior to study entry are eligible.~* Began therapy with male sex hormones 24 weeks prior to study entry. Patients who have had continuous, stable therapy with male sex hormones for 24 weeks or more prior to study entry are eligible.~* Certain medications within 14 days prior to study entry~* Serious illness within 14 days prior to study entry~* Hepatitis within 60 days prior to study entry~* Thyroid problems~* Drug or alcohol use which, in the opinion of the investigator, would interfere with the study~* Currently using experimental agents except when approved by the study~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females aged 18 to 60 years (inclusive) with moderate to severe chronic plaque psoriasis who require systemic treatment.~Exclusion Criteria:~* Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.~* Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections.~History or presence of malignancy.~* Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Investigational drug - Dose 1 (Type: EXPERIMENTAL): None
- Investigational drug - Dose 2 (Type: EXPERIMENTAL): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maternal-Offspring Metabolics:Family Intervention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45 years~* Singleton viable pregnancy. A twin pregnancy reduced to singleton before 14 weeks by project gestational age. An ultrasound must be conducted before randomization that shows a fetal heartbeat; there should be no evidence of more than one fetus on the most recent pre-randomization ultrasound.~* Gestational age at randomization no earlier than 9 weeks 0 days and no later than 15 weeks 6 days based on an algorithm (see Section 3.4.3 below) that compares the last menstrual period (LMP) date and data from the earliest ultrasound~* Body mass index between 25-35 kg/m2 based on first trimester measured weight and on measured height. The earliest weight measurement before randomization, measured specifically for the study will be used.~Exclusion Criteria:~* In vitro fertilization (IVF) conception/ovulation induction w/ gonadotropins~* Weight gain of \>15 pounds from reported prepregnancy weight to Baseline visit~* Current smoker~* Prior bariatric surgery~* In weight loss program w/in 3 months of conception~* History of alcohol or drug abuse within 5 years~* No access to internet and/or smartphone~* Unable to attend intervention/follow-up visits~* Unwilling/unable to commit to self-monitoring data collection~* Unable to complete intervention program~* Presence of any condition that limits walking or following diet recommendations~* Not fluent in English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care Group (Type: ACTIVE_COMPARATOR): Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
- Lifestyle Intervention Group (Type: EXPERIMENTAL): Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion in this trial, the patient must have moderate to severe chronic graft-versus-host disease \[defined by the National Institutes of Health (NIH) 2015 Consensus Criteria\] that started within 3 years after hematopoietic stem cell transplantation (HSCT).~Exclusion Criteria:~* Is intolerant to corticosteroids or hypersensitive to methoxsalen~* Received certain treatments during time periods disallowed by protocol~* Has infections and/or requires treatment that (per protocol or in the opinion of the investigator) might compromise:~  1. safety and well-being of participant or offspring~ 2. safety of study staff~ 3. analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ECP Methoxsalen + Standard of Care (Type: EXPERIMENTAL): Participants receive methoxsalen administered via ECP in addition to standard of care
- Standard of Care (Type: ACTIVE_COMPARATOR): Participants receive standard of care only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Competent and willing to voluntarily provide informed consent~* 18 years of age or older~* In good general health needing to undergo cataract extraction or lens extraction with lens replacement surgery in one eye, under topical anesthesia~Exclusion Criteria:~* No allergies to the medications and/or the active ingredients of any of the study medications~* No medications with the same activities of the active ingredients in OMS302 for defined time intervals prior to and after surgery~* No other significant eye injuries, eye conditions or general medical conditions likely to interfere with the evaluation of the study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMS302 (Type: EXPERIMENTAL): OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete